Navigation Links
Peptimmune Files Citizen Petition Regarding Generic Copaxone and Demonstrates Significant Enabling Technology for Biological Characterization of Copaxone
Date:10/4/2010

ce for a generic copy of Copaxone should include the comparative PK and PD studies proposed in the Citizen Petition.  Our studies demonstrate a direct correlation between Copaxone serum exposure and activation of the innate immune system.  Controlling this relationship in particular is critical to ensure safety and therapeutic effect of any generic copy of Copaxone.  The effect of Copaxone cannot just be simply explained by induction of regulatory T cells; its effect on antigen presenting cells is just as important.  Systemic exposure of Copaxone facilitates the direct effect on monocyte activity, perhaps even in the brain.  If a generic manufacturer primarily limits its characterization of a generic copy to comparative antibody responses or T cell responses they could be significantly underestimating the copy's biological effects."

The Citizen Petition is available for download at www.peptimmune.com/news.

About Multiple Sclerosis

Over 400,000 Americans have multiple sclerosis (MS), and MS may affect over 2.5 million individuals worldwide.  MS is an autoimmune disease in which the individual's immune system responds against multiple components of nerve-insulating myelin.  The effects of these immune-mediated attacks can range from relatively benign to somewhat disabling to devastating, as communication between the brain and other parts of the body is disrupted.

About Peptimmune

Peptimmune, Inc. is a privately held clinical stage biotechnology company focused on the development of PI-2301, a second-generation peptide copolymer from a similar compound class as Copaxone. PI-2301 has shown to be more potent and effective than Copaxone in treating disease models for multiple sclerosis. The Company plans to continue developing this promising compound by initiating a Phase II study in relapsing remitting multiple sclerosis patients later this y
'/>"/>

SOURCE Peptimmune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Peptimmune Initiates Phase I Study With a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
2. Peptimmune Completes Phase I Study with a Novel Peptide Copolymer for the Treatment of Multiple Sclerosis
3. Peptimmune Presents Early Clinical Data at European Neurological Society and Federation of Clinical Immunology Societies Meetings
4. Peptimmune Initiates Phase Ib Study of PI-2301 in Multiple Sclerosis Patients and Presentation at BIO 2008
5. Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
6. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
7. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
8. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
9. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
10. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
11. Further Clinical Testing of BZL101 in Advanced Breast Cancer Demonstrates Favorable Efficacy and Toxicity Profiles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... 2013 Faruqi & Faruqi, LLP, a ... securities fraud at AVEO Pharmaceuticals, Inc. ("AVEO" or ... http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) The investigation focuses ... federal securities laws by issuing materially false and/or ... trials for Tivopath (tivozanib) (titled "TIVO-1").  Specifically, the ...
(Date:5/17/2013)... , May 17, 2013  Sorrento Therapeutics, Inc. ... Fast-Track Advanced Technology Small Business Technology Transfer Research ... Allergy and Infectious Diseases (NIAID), a division of ... development of novel human antibody therapeutics to combat ... or Staph) infections, including methicillin-resistant S. aureus ...
(Date:5/17/2013)... 2013  Sony Biotechnology Inc. ("Sony") today announced the launch ... 130um sorting chip.  Sony will also be exhibiting its newly ... Cell Sorter, the EC800 flow cytometer, and new SP6800 Spectral ... which will be held at the San Diego ... , from May 20 - 22.  ...
Breaking Medicine Technology:Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Sony Delivers New Technology for Science to CYTO 2013 2
... & LUND, Sweden--(BUSINESS WIRE)--May 1, 2007 - ... today,announced that data from a 36-week, randomized, ... oral 0.6 mg,dose of laquinimod given daily ... by 38 percent in RRMS,patients and was ...
... pivotal phase III study in women with recurrent ... 2007,/PRNewswire-FirstCall/ -- A new study further supports the ... being,studied for the treatment of ovarian cancer. The ... protein, which triggers,a series of events that selectively ...
Cached Medicine Technology:Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 2Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 3Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 4Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 5Laquinimod, a Novel Oral Compound, Showed Significant Reduction in,Disease Activity in Patients with Relapsing-Remitting Multiple,Sclerosis (RRMS) 6New Research Results Show That Investigational Drug Phenoxodiol,Targets Cancer Protein, Causing Cancer Cell Death 2New Research Results Show That Investigational Drug Phenoxodiol,Targets Cancer Protein, Causing Cancer Cell Death 3New Research Results Show That Investigational Drug Phenoxodiol,Targets Cancer Protein, Causing Cancer Cell Death 4New Research Results Show That Investigational Drug Phenoxodiol,Targets Cancer Protein, Causing Cancer Cell Death 5
(Date:5/18/2013)... Medical device company, FlexLeg, LLC, last week ... mobility aid with its namesake, the FlexLeg. The device ... alternative that injured individuals can use to walk on ... remain active and walk during a typical 6-8 week recovery ... to ensure those who need the device most are able ...
(Date:5/18/2013)... Phoenix, Arizona (PRWEB) May 18, 2013 ... umbrella – two health and wellness centers and one ... at all three locations, the weekend of May 25th ... personnel and celebrating Memorial Day. All events ... , Saturday, May 25th , Elements Therapeutic Dispensary , ...
(Date:5/17/2013)... 18, 2013. Chronic trauma can inflict lasting damage to ... studies of people with post-traumatic stress disorder, or PTSD, ... in response to stressful tasks, such as recalling a ... threatening face. Now, researchers at NYU School of Medicine ... the brains of combat veterans with PTSD in the ...
(Date:5/17/2013)... 2013 Allen J. Schultz, D.D.S., is making ... treatment available to residents of San Juan Capistrano. ... tissue rather than relying on a scalpel to cut the ... that works on tightly defined wavelengths to target the diseased ... intact. , Only about one in every hundred dental professionals ...
(Date:5/17/2013)... Spring floods, summer droughts and temperature extremes take ... them. Help gardens recover from the crazy temperature and ... Myers suggests the following steps to revive gardens and ... the current condition of the landscape. Remove dead plants ... disease organisms that can infest healthy plantings. Consider replacing ...
Breaking Medicine News(10 mins):Health News:FlexLeg Begins Offering New Mobility Aid 2Health News:Elements Honors Medical Marijuana Patients at Elements Health and Wellness Centers and Elements Therapeutic Dispensary 2Health News:Elements Honors Medical Marijuana Patients at Elements Health and Wellness Centers and Elements Therapeutic Dispensary 3Health News:Elements Honors Medical Marijuana Patients at Elements Health and Wellness Centers and Elements Therapeutic Dispensary 4Health News:For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests 2Health News:San Clemente, CA Periodontist, Dr. Allen J. Schultz, Now Provides Laser Gum Disease Treatment to Southern Orange County Periodontal Disease Patients 2Health News:Garden Revival: Gardening Expert Melinda Myers Shares Tips for Helping Gardens Recover From Extreme Weather Conditions 2Health News:Garden Revival: Gardening Expert Melinda Myers Shares Tips for Helping Gardens Recover From Extreme Weather Conditions 3
... a cost-effective form of treatment for Americans,with ... Patients with,diabetes who participate in a program ... improvements in glucose control,physical performance, and body ... the November 2008 issue of Physical Therapy ...
... PURCHASE, N.Y., Oct. 31 Nutrition 21, Inc.,(Nasdaq: ... that,help consumers manage blood sugar levels, improve cardiovascular health,enhance ... results -- prior to the opening of the market ... of fiscal year 2009, ended,September 30, 2008. The Company ...
... more dangerous if publicized , , FRIDAY, Oct. 31 (HealthDay ... the threat of infectious diseases, Canadian researchers say. , ... to be regarded as especially dangerous by the public, ... tend to focus on rare and dramatic events. When ...
... Oct. 31 Blue Cross Blue Shield of Michigan ... bomb threat,received this morning., The closings affect Blue ... and Bricktown Customer Service Center,buildings. The company,s office building ... employees who work in the impacted facilities are,being sent ...
... have previously shown that E2 and P4 have clear ... changes during early H. pylori infection. Recently, Ohtani et ... in H. pylori-infected InGas mice. Other studies have demonstrated ... gastric mucosa. ER and PR have been reported in human, ...
... Your Vet for a Healthy Pet(R), contest sponsored ... Inc., DENVER, Oct. 31 Veterinarians provide ... for long, healthy and happy lives. To,recognize their ... for the "Thank Your Vet for a Healthy ...
Cached Medicine News:Health News:New Research Shows That Combining Aerobic Exercise With High-Force Eccentric Resistance Training Improves Glucose Control in Diabetes Patients 2Health News:New Research Shows That Combining Aerobic Exercise With High-Force Eccentric Resistance Training Improves Glucose Control in Diabetes Patients 3Health News:Nutrition 21 to Report Preliminary First Quarter Fiscal Year 2009 Financial Results on Thursday, November 13, 2008 2Health News:Media Affects Public Perception of Infectious Diseases 2Health News:Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils 2Health News:Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils 3Health News:Hundreds of Pet Owners Nominate Veterinarians in Nationwide Contest to Find America's Best Vet 2Health News:Hundreds of Pet Owners Nominate Veterinarians in Nationwide Contest to Find America's Best Vet 3
... Surgical Markers allows the surgeon ... with a scrub-resistant, gentian violet ... are provided sterile, with a ... in peel pouches. Micro tip ...
... violet ink stands up ... scale ruler printed on ... quick measuring. Flexible, smudge-proof ... inch and metric scales. ...
Broad tip, gentian violet, sterile, disposable...
Double-ended, one end sharp, other end blunt, 7 1/2", double-ended, 5 mm wide....
Medicine Products: